1Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, et.al (2016) RRx-001, A novel dinitroazetidine radiosensitizer. Invest New Drugs. 34:371-377.

2Ning S, Bednarski MD, Oronsky B, Scicinski J, Saul G, et.al (2012) Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 72:2600-2608.

3Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, et.al (2017) The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clin Epigenetics. 19:9:4.

4Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, et.al (2012) Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative antic- ancer agent. Drug Metab Dispos. 40:1810–1816.

5Reid T, Oronsky B, Scicinski J, et.al (2015) Safety and activity of RRx-001 in patients with advanced cancer: a firstin- human, open-label, dose- escalation phase 1 study. Lancet Oncol. 16:1133-1142.

6Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE, et.al (2017) RRX-001 protects against cisplatin-induced toxicities. J Cancer Res Clin Oncol. 143:1671-1677.

7Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl DM, et.al (2015) Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001. Oncotarget. 6-21547- 21556.